Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
Status:
Completed
Trial end date:
2020-11-19
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with
generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive
daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.